What It Takes to Create a Successful Research Program


Answers From the Lab

Published November 19, 2026

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss recent infectious disease news. Dr. Pritt then welcomes Peter Lucas, M.D., Ph.D., vice chair of research for the Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester. Together, they explore the importance of research in laboratory medicine and what it takes to build a robust research program.

  • Infectious disease updates (00:01): Drs. Pritt and Morice discuss the value of laboratory testing amid respiratory virus activity and an increase in dengue cases.
  • The value of research (06:36): Learn why research and discovery are essential to advancing laboratory medicine and pathology.
  • Building a strong research program (10:48): Hear how Dr. Lucas is working to build a robust research program that generates valuable insights to advance clinical testing and ultimately support better patient care.

Transcript

Bobbi Pritt, M.D. (00:05):

Hello, I'm Dr. Bobbi Pritt, a clinical microbiologist and laboratory leader at Mayo Clinic, and your host for today's episode. I'm excited to be here today with Mayo Clinic Laboratories CEO and president, Dr. Bill Morice. We're going to get the latest news, and then I will be speaking with Dr. Peter Lucas about laboratory medicine research at Mayo Clinic during our deep dive. Bill, it's great to have you.

William Morice II, M.D., Ph.D.  (00:28):

Yeah, it's great to be here as always, Bobbi.

Bobbi Pritt, M.D. (00:30):

Yeah. You know, we have some really timely topics. One, I think, is that we are approaching respiratory virus season. And in fact, you know, just last month, Dr. Binnicker gave us an early look into what to expect for the respiratory virus season. Well, we are now entering it. And we're actually starting to see reports of influenza activity this fall, reaching levels in some areas of the country that we usually don't see until January. So, I think it's a good topic for us to talk about now.

William Morice II, M.D., Ph.D.  (00:59):

Yeah, absolutely. Very timely for me, because I'm in Chicago visiting my parents. And so, they just got vaccinated themselves, and it's really important to think about staying out in front of these respiratory viruses, because as we know, they can really have a major impact on individuals and really on groups of people as well.

Bobbi Pritt, M.D. (01:20):

Yeah, absolutely. There are definitely groups that are at increased risk, but then anyone, even someone who's otherwise healthy, could still have a very bad bout of COVID or influenza. And so, it's important to consider. And I know that some people don't even think about getting their vaccinations until later in the year, but I think now that we have influenza circulating, it's probably just best to go now, get your vaccinations.

William Morice II, M.D., Ph.D.  (01:44):

That's right. And then remembering though also, the vaccines certainly do help, but they're not 100%. So, you still need to practice good care. And also, we need to make sure that the diagnostic tests are available, because there's more than one respiratory virus around, and there are now specific therapies and also different risk profiles for different viruses. So particularly again, I talk about at-risk, like my parents, really important that we get an accurate diagnosis if they do indeed catch a respiratory virus. But the first thing is to try and prevent. As you've talked very well, in arthropod‑borne diseases and everything else.

Bobbi Pritt, M.D. (02:19):

Yeah. So, it gets to the points that we've been making for many years now. Masking if you're not feeling well, staying home from big gatherings if you're not feeling well. In fact, I just had a big Halloween party for folks from my division of clinical microbiology, and I had some people who didn't come because they just weren't feeling well. And I think that's, you know, we miss them a lot, but it's completely appropriate. If you don't feel well, don't go to a big gathering and have other people not feeling well as a result.

William Morice II, M.D., Ph.D.  (02:49):

That's right. And particularly if you're someone that's at risk and you have pulmonary disease or immunosuppression, really think about wearing a mask when you're out. Certainly, air travel is busier than ever, you know? There's been a lot of return to work, and so there's a lot more people interacting. So, just really be mindful. Again, if you can avoid going out, if you're feeling ill, that's best. And if you're going out and you think you might be at risk, think about hand-washing, thinking about wearing masks, thinking about some sorts of things that can really help keep you protected.

Bobbi Pritt, M.D. (03:21):

Yeah. So just kind of to summarize, I think Bill, you've brought up a lot of good points. We talked about masking, prevention, but again, the role that laboratory medicine plays is testing for individual cases, but then also strain monitoring. And I'll just briefly mention there is a variant strain right now, mutated strain, some people are calling it, of influenza. It's the H1N1 virus that arose back in 2009. It has this mutation at this location, G155E. And we would not have been able to really monitor and track these types of mutations so quickly and easily had it not been for COVID and all the experience that we had with viral sequencing. So, all of those different takeaways with individual viral testing, but then also our ability to detect and track and monitor new emerging strains of viruses.

William Morice II, M.D., Ph.D.  (04:14):

That's right. We know a lot more. We can do a lot more in the laboratory, but best of all to prevent yourself from getting sick if at all possible or spreading it if you are.

Bobbi Pritt, M.D. (04:22):

Right. So just in our last minute, I thought I'd briefly talk about another virus, and that's dengue virus. And dengue is something we classically think of in tropical, subtropical settings, but we've been having outbreaks in the Americas, in India, Puerto Rico, and there has been an increase in dengue cases in Florida here in our continental United States. This is something that we've talked about before. We have the vectors in Florida, and it's very easy for pathogens to move when you have the vectors. In fact, the vectors move. So, I think this also gets to the role of laboratory testing. I don't know if you have any thoughts on that.

William Morice II, M.D., Ph.D.  (05:02):

I was visiting in Brazil, I think about a year ago, and they were dealing with a pretty severe dengue outbreak. It can be a real problem. And I think about this, I think about the screwworm, which is now beginning more and more in the news. Can they have genetically modified screwworms to try and prevent transmission like they've done with some other diseases? But the thing is, number one, it's not just having the test, but helping support the clinicians and the doctors that are seeing patients to even think about these things. You know, what we're seeing is that, as the world changes, pathogens are getting outside of what we think of as, air quotes, classical, areas of distribution in the world.

Sometimes clinicians might not even think of it. And so, we need to be able to support them both in thinking about it, but then having the confirmatory diagnostics as well. So, it's just a world that we really have to be ready to be vigilant and adapt. And then there's real serious viruses that have ongoing outbreaks, like Ebola. So, we have to keep the labs as a knowledge center for the healthcare centers that we serve, and also have the right armamentarium of tests either in our labs or through a reference lab or public health lab that you have a good relationship with so that you can make sure you get an accurate diagnosis.

Bobbi Pritt, M.D. (06:15):

Yeah, really well said. Well, I think those were a couple of great topics, and I'll look forward to our next meeting soon to talk about more hot topics.

William Morice II, M.D., Ph.D.  (06:23):

Yeah. There never seems to be a shortage, so I look forward to it.

Bobbi Pritt, M.D. (06:26):

Thanks, Bill. Welcome to today's deep dive. I'm pleased to be joined by Dr. Peter Lucas, vice chair of research for the Department of Laboratory Medicine and Pathology at Mayo Clinic. Dr. Lucas joined us a couple of years ago to share his vision for DLMP's research activities. It seems like just yesterday, and I'm very excited to welcome him back to the show. Dr. Lucas, thank you so much for being here today.

Peter Lucas, M.D., Ph.D. (06:56):

Thank you so much for having me, Dr. Pritt. It’s great to be here again.

Bobbi Pritt, M.D. (06:59):

Dr. Lucas, I have a number of questions for you. I'll start with a basic one, though, for our listeners. Why is research in lab medicine and pathology so important?

Peter Lucas, M.D., Ph.D. (07:09):

That's a great question, obviously. Well, if you think about the clinical mission of our department, laboratory medicine and pathology, it's all about testing, right? It's almost everything that we focus on, and that includes diagnostic tests, answering what's the disease that a patient is encountering, and oftentimes what's causing that disease. It's about prognostic tests, how is the patient going to do, predictive tests that inform the potential efficacy of therapies. And so, all of these tests that help our clinical care and our clinical colleagues are grounded in a deep understanding of the fundamental mechanisms of disease. So these tests are the result of decades of research into those fundamental processes. And, we simply wouldn't have any tests if it weren't for this research. And so, we're constantly seeking to iterate on that knowledge, continuing to research disease and disease processes so that we better understand those molecular underpinnings, with the mindset of turning that new knowledge into new and more precise tests that have clinical value.

It's the discovery-to-translation pipeline. With that pipeline of research leading to increasingly informative tests, we in DLMP are able to better equip our clinical colleagues, provide better care for our patients. And, you know, I'll give you just one example of how research informs that. This past year, one of our superstar researchers, Dr. Fergus Couch and his lab team, published a landmark paper in the journal Nature. It's one of the highest impact biomedical journals out there. And in that paper, they defined the functional and clinical meaning of almost every possible DNA sequence variation or alteration that could happen in the BRCA2 gene. It's one of the key breast cancer predisposition genes. Because the problem in the field had been that BRCA2 is a huge gene and there are many, many possible sequence variations that can occur in that gene. But it was really unknown how many of those alterations and which of those actually led to a meaningful increase in cancer risk for patients.

So, a patient could get a genetic test and receive a report that said they had a variant in the gene, but very often, it was unclear if that variant was actually pathogenic, meaning it had a truly impactful risk for cancer development for that patient, or whether it was just an inconsequential variant in the DNA sequence of the gene, which happens. And so, patients and the doctor caring for the patient might not know what to do about it. But now, with this research from Dr. Couch's lab, defining the functional meaning of almost every possible variant they could have in that gene, that empowers patients and clinicians to make more decisive clinical action, to understand that test in a better way. That's an example of improving prognostic value of our testing coming from basic research. Research provides knowledge that informs our testing.

Bobbi Pritt, M.D. (10:29):

That was really well said, and what a great example showing how you need the research to then help drive the testing and the clinical care and pulls it all together. So, really, really nicely summarized for us. So, we know it's important. We want to be able to advance the field of research. What does it take to build and sustain a successful research program?

Peter Lucas, M.D., Ph.D. (10:50):

Yes. So, I'm glad you asked that because it's something I've been thinking a lot about since coming to Mayo, something I've spoken about, I'm really passionate about. I've tried to message the idea that we want Mayo DLMP to be the place that literally everyone everywhere thinks of as the place that's driving transformative practice-changing research and pathology. That's the vision. So, how do we get there? I think there are four key elements that I oftentimes talk about how to build that vision. That's essentially our mission. And it revolves around, number one, people. It's the idea to get the right people on the bus, and it's going to go somewhere great. It's one of the key messages from a book that I'm really passionate about called “Good to Great” by Jim Collins. It's a fantastic study on how certain organizations distinguish themselves from others and become truly great.

And it's about getting the right people on board, retaining great talent, recruiting talent from the outside when you think it's going to add value. And so, I think focusing on people, not necessarily having a preconceived notion of what those people are going to do, but having those people, great things are going to happen. And then infrastructure is number two. We have to make great spaces and resources available to those people. Right now, we are nearing completion of a total gut and renovation of the second floor of the Stabile Building, which is right next door to the Hilton Building, where many of our clinical labs are located. And that floor is being reconstructed in the open lab format, which means there are no walls, open blended lab spaces that really maximize flexibility, foster interactions, and this is where a lot of our basic research is taking place.

So, we're trying to create a really inspiring space to support those people. The third thing is funding. You know, you've heard the phrase, no money and no mission. Well, it's very true, and we're working hard to support our research programs with that funding, helping folks secure grants from a variety of sources, diversifying our funding portfolio. It's important that we have NIH funding. At the same time, we want to diversify to include foundation grant awards, industry sponsorships, internal support from our own department in Mayo. So, that's a big piece of it. The final thing is programs. We think we have some of our greatest impact when we coalesce efforts around a defined number of priorities. And so, we've taken a deep dive to kind of look broadly across the research portfolio in DLMP to find and understand, where are the areas where we have really special growth, where we have special foundation, and standing those up as research pillars and making sure we can articulate that to everyone, both inside and outside of DLMP, so that there's kind of optimal clarity about what makes our research programs especially impactful or special. So people, infrastructure, funding, and programs, that's what I think about.

Bobbi Pritt, M.D. (13:52):

I love that. Those are four really powerful foundations to build upon. And I believe one of your pillars is infectious diseases testing, correct?

Peter Lucas, M.D., Ph.D. (13:59):

That is correct, yes.

Bobbi Pritt, M.D. (14:01):

One of my favorites. So, what are some of DLMP's key research focus areas? And you've touched on this a little bit, but what are some of the advantages of a focused approach?

Peter Lucas, M.D., Ph.D. (14:13):

Yeah. Because pathology is so broad and we do things that touch on every aspect of disease, we do research across every aspect of disease. Sometimes I think that can make our message a little diffuse. And so, this is why we are trying to stand up these pillars and articulate what those pillars are. We've come up with six pillars, and it's not something that I think of as set in stone. It can be evolving. But right now, our six pillars, we have two technology-focused pillars. And the first one is digital pathology and AI, which as you know, is an incredibly hot area where work is being done to leverage information that's embedded in the images of our humble H&E stains that we use routinely across microscopic pathology. A second one is spatial biology and multiomics, also very hot.

This is the use of new technologies that allow us to profile hundreds and sometimes even thousands of molecules, all at the same time in a highly multiplexed manner across just a single tissue section. Those two areas aren't completely distinct or siloed. In fact, I think one informs the other, and if they're used together, they can really be a powerful engine for transformative discoveries, and they can be used across our other pillars. Our other four pillars are more disease-focused. One is neurodegenerative diseases and neuroimmunology. We've got a great history and strength in that area going back to the foundational work of Dr. Vanda Lennon, who built the strong neuroimmunology component to our department. And we also have, as you mentioned, infectious diseases, or pathogen-associated diseases, where we have great strength in Robin Patel and Trish Simner and yourself, just leading the field in basic and clinical microbiology.

Solid tumors, lots of strength there. And so, the last one is hematologic malignancies and stem cells. That's sort of the counterpart to the solid tumor pillar, includes research into blood-based diseases like leukemia and lymphoma. This is an area of specialty for our chair, Dr. Eric Hsi. And also, we have related work in there in stem cell biology that has a lot of relevance to some of the therapeutic work being done in the department in transfusion medicine. Although we have six pillars, we don't want them to be isolated, and this all works best when there is work done across pillars. And I've got a great example of that. Dr. Jansen Seheult in hematopathology, along with our chair, Dr. Eric Hsi, and Dr. Wenchao Han, who is in the Division of Computational Biology Informatics, they've worked to blend the technology of digital pathology and AI, that's pillar one, with lymphoma research, that's pillar six, to develop something that they've called LymphoVision. It's really taken the field by storm. It's essentially a computer vision strategy to categorize lymphomas based on only that H&E image and AI algorithms to interpret those images and then add prognostic value and predictive value. The capabilities are continuing to grow. And that's really something that previously is inconceivable, because so much of our understanding of lymphoma categorization has depended on a detailed molecular analysis. So, to be able to recapitulate that with, again, the humble H&E slide, and AI interpreting that slide, is really amazing. And I think it's just the beginning. That's just one example of work bridging more than one pillar, and that's where I think a lot of the strength comes.

Bobbi Pritt, M.D. (17:55):

That's a great example, Dr. Lucas. You know, it's very exciting what you're working on. And of course, for me, the infectious disease and microbial component, but all of these areas, I love how they span all of laboratory medicine and pathology. Well, Dr. Lucas, I'll just end by asking one last question, and it's about structure. You've talked a little bit about how you've defined the programs, but I know that DLMP also made changes to more closely integrate discovery research with actual clinical and translational efforts. What benefits do you think this will bring?

Peter Lucas, M.D., Ph.D. (18:28):

Yes, that is absolutely right. So, you know, historically, we've had this division called Experimental Pathology and Laboratory Medicine. It's the one division in the department that's dedicated solely to research with no clinical role. And that was very purposeful, to allow members to pursue knowledge and discoveries without having to be constrained by a clinical mission or a clinical need. And at the same time, the risk of that structure is that the division can be a little bit siloed and not connected with the rest of the department. So this year, we've taken this big step towards restructuring the division to allow it to still be our hub for discovery research, and at the same time, more inclusive and increasingly integrated, which I think helps grow that discovery translation pipeline. And so, we've opened up membership to the division to include secondary members across all of our divisions, bringing in faculty whose career path really incorporates research in a very significant way.

And at the same time, we've taken the opportunity to rename the division. The new name is cleaner and more concise. It's now called Investigative Pathobiology, IPB. We have to abbreviate things. And there's meaning behind that. We've essentially substituted experimental for investigative, because we recognize now that not all of the great science being done is based on an experiment. In the modern era, some of it's AI, informatics. And then we use the term pathobiology instead of pathology because this sort of emphasizes that we're working towards understanding how disease develops the most fundamental underpinnings and not just the end result of pathology. So, I think this integration of that research hub division in the department with membership across the department really helps integrate our discovery efforts with that translational pipeline.

Bobbi Pritt, M.D. (20:20):

I love that. And I'm really excited to see what's now going to come out of the new reorganization and all the people you've pulled in, really making it a big team effort as we do with everything at Mayo Clinic, and it's always been so positive and fruitful. So thanks again, Dr. Lucas, for joining us. It's been really interesting to hear about your vision and the new structure. I'm sure we'll have you back maybe in another couple years and to talk about some of the great work you're doing.

Peter Lucas, M.D., Ph.D. (20:47):

That sounds great, Bobbi. We'd love to come back. Appreciate it.

Bobbi Pritt, M.D. (20:55):

Let's wrap up with the top takeaways and how to learn even more on the topics we've discussed. During the news, we discuss current influenza activity in the United States and rising dengue cases in Florida. And in the show notes, you'll find links to learn more about testing for respiratory and vector-borne diseases, including dengue, which is spread by mosquitoes. And then in the deep dive, I welcomed Dr. Peter Lucas to discuss the importance of research and how he's fostering innovation as vice chair of research for Mayo Clinic's Department of Laboratory Medicine and Pathology in Rochester, Minnesota. Check the show notes for a previous episode featuring Dr. Lucas and his approach to laboratory medicine research. Thank you for joining us today. If you haven't already, make sure to subscribe so you never miss an episode. Next time, Dr. Morice and I will dive into some of our accomplishments from 2026 and what they mean for advances in our industry in 2027. I hope you can join us.

Note: Information in this post was accurate at the time of its posting.

Resources

Connect with Us

  • Is there a question or topic you’d like us to explore in a future episode? Email us at mayocliniclabs@mayo.edu.
  • Learn more about our hosts and guests and connect with them on social media.

Subscribe

Mayo Clinic Laboratories’ “Answers From the Lab” podcast is available on your favorite podcast platforms. Subscribe on your preferred app to stay up to date and never miss an episode.

Video

Mayo Clinic Laboratories

This post was authored by the Marketing Team at Mayo Clinic Laboratories.